By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Expression Pathology today announced a collaboration with the University of Texas MD Anderson Cancer Center for the evaluation of the company's Liquid Tissue SRM technology.
By Adam Bonislawski
Theranostics Health has licensed a new fixative developed by researchers at George Mason University that could significantly improve the quality of tissue samples available to proteomic researchers.
Under the terms of the deal, Expression Pathology will use its Liquid Tissue SRM technology to develop multiplexed quantitative mass spectrometry assays for the detection of cancer signaling pathway proteins in FFPE tissue samples.
The deal combines Expression Pathology's mass spec-based assays for FFPE tissue with Flagship's pathology expertise, allowing the partners to identify tissue features or sub-anatomic organelles of research interest and then extract and prep them for proteomic analysis.
The partnership will enable tissue translational biomarker development, validation, and application to support new drug development, according to Flagship Biosciences.
The company's most recent deal to apply its technology for assay development is "part of a broad program we have embarked on to exploit our unique ability to apply mass spectrometry to FFPE tissue," a company official said.
The goal is to develop an alternative to immunohistochemistry that would be "more sensitive and provide high-quality quantitative information about a much wider range of specific proteins that are suspected of being markers for cancer," Thermo Fisher said.
